All previous treatments are acceptable as long as they did not contain bevacizumab, ramucirumab or PARP inhibitors
Has received treatment with any proscribed treatments within specified time frames prior to study drug administration
Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted
Prior history of receiving pazopanib treatments
Total carmustine (BCNU) dose of > 600 mg/m^2 with prior treatments including transplant conditioning regimen
More than two prior systemic treatments for MDS. Prior systemic therapies are those that have been received at standard doses for at least one full treatment cycle.
Any other cancer treatments within 2 weeks of planned study treatment
progressed during or within 3 months of completing adjuvant chemotherapy. Note: Generally, treatments that are separated by an event of progression are considered different regimens.
Pregnant or lactating as the treatments used in this study includes drugs that are FDA Pregnancy Category D.
At least 2 weeks post any treatments/therapies at the time of first dose.
All patients with verified diagnosis of LCH and MRI findings consistent with ND-CNSLCH irrespective of previous treatments (also those not registered to other Strata ofLCH-IV).
Previous liver-directed treatments including chemoembolization, radiosphere, hepatic arterial perfusion, or drug-eluting beads
Have discontinued previous treatments for cancer.
Condition requiring medication with potential photosensitizing effects (tetracyclines, quinolones, sulphonamides, phenothiazines, sulfonylurea hypoglycaemic agents, thiazide diuretics, griseofulvin, and amiodarone) if these treatments could not be stopped at least 10 days before and for 3 days after the VTP procedure or replaced by treatments without photosensitizing properties;
Any number of prior treatments allowed for patients under 65 years (y), over 65y must have at least one prior line of TKI treatment (excluding anaplastic patients).
Patients may have unlimited prior chemotherapy treatments
Additional prior systemic treatments not allowed
Discontinued all previous treatments for cancer ?4 weeks prior.
No restriction based on prior treatments but at least 4 weeks from prior immunotherapy, or prior investigational agents
Subject has history of severe infusion reactions related to prior biologics or antibody-based treatments
There is no limit to the number of prior treatments for this phase I trial
Has disease which is amenable to radical treatment with surgery or radiation or a combination of treatments
There is no upper limit on the number of prior treatments provided all inclusion/exclusion criteria are met
Patients with histologically confirmed peritoneal surface malignancies, including malignant peritoneal mesothelioma and peritoneal carcinomatosis (PC) from presumed appendiceal and colorectal primary tumors; most patients will have received extensive prior treatments, due to the recurrent nature of PC; prior therapies involve previous CRS, local and systemic chemotherapy, and their different numbers; none of these prior treatments disqualifies the patient from receiving the protocol-mandated experimental treatment
If sexually active, patients must agree to take contraceptive measures for the duration of the treatments
No restriction based on prior treatments
Has undergone ?3 previous regimens (depending on treatment arm) of cytoreductive therapies including, but not limited to, platinum-based compounds, taxanes, or 5-fluorouracil. for B7, no prior systemic treatments should have been received for RM SCCHN
Patients who have received prior EGFR treatments for lung cancer
Receiving other treatments for the condition (with exceptions and time limits)
Patients must have the following minimum wash-out from previous treatments:
Has received any treatments prohibited in this trial within specified time frames
Prior history of receiving pazopanib treatments
Recovered from acute toxicities of other treatments (? Grade 2). All other MDS treatments discontinued at least 4 weeks prior to treatment except epoetin alpha (Procrit) 2 weeks.
Subject is receiving prohibited medications or treatments that cannot be discontinued/replaced by an alternative therapy
After the T cell infusion, patients may not be on any other treatments for their cancer aside from those included in the treatment section of the protocol
Ongoing toxic manifestations of previous treatments.
Off all other treatments for MDS for at least 2 weeks prior to Screening.
Participants receiving the following medications or treatments within the 6 weeks (42 days) prior to consenting; these medication and treatments may not be re-started at any time throughout the study in order to be remain eligible:\r\n* Breast tumor resection surgery (reconstructive surgery permitted)\r\n* Chemotherapy\r\n* Radiation therapy\r\n* Allergy desensitization injections\r\n* Growth factors (Procrit, Aranesp, Neulasta)\r\n* Other agents with putative immunomodulating activity (with the exception of non-steroidal anti-inflammatory agents)\r\n* Any investigational medication
There is no limitation to prior treatments with local, regional, topical or systemic agents, except for prior systemic treatment with 5-fluorouracil or prodrugs thereof; prior topical treatment with 5-fluorouracil is permitted; patients who are on chronic daily doses of prednisone of greater than 10 mg are excluded; there is no restriction on timing of last treatments as long as patients have recovered from all expected toxicities and at least 21 days have passed since last administration
Patients are allowed to have up to 3 prior treatments
Prior anticancer treatments or therapies within the indicated time window prior to first dose of study treatment (ASTX660), as follows:
Patients with no more than 2 prior treatments with systemic anti-neoplastic therapy for CCA.
Have discontinued previous treatments for cancer;
Allowed prior treatments for localized prostate cancer (all treatments must have been completed >= 1 year prior to randomization) a) <= 3 years total of ADT; b) All other forms of prior therapies including radiation therapy, prostatectomy,lymph node dissection, and systemic therapies
Have ongoing clinically significant adverse event(s) due to prior treatments administered as determined by the investigator.
At least four weeks must have elapsed between the last dose of any MF- directed drug treatments for myelofibrosis (including investigational therapies) and study enrollment;
Patients previously treated with herbal supplements, or other potential or experimental therapies for prostate cancer (apart from LHRH agonists and antiandrogens), must have been discontinued these treatments and completed at least a one-month washout prior to first vaccination
No restriction based on prior treatments
No restriction based on prior treatments
Receipt of > 600 mg/m^2 total dose of carmustine (BCNU) with prior treatments including transplant conditioning regimen
Patients may not be on any other treatments for their cancer aside from those included in the protocol. Patients may not undergo another form of treatment concurrently with this study. Oncology supportive treatments such as growth factors, bone modifying agents, pain or nausea management are allowed.
Prior systemic cytotoxic chemotherapies and/or novel immunotherapy treatments for MCC are allowed. A wash-out period of 2 weeks prior to aNK treatment will be required.
The participant may have had any number of prior systemic cytotoxic therapies for advanced/metastatic disease and are considered appropriate candidates for anthracycline therapy. All previous anticancer treatments must be completed ? 3 weeks (21 days) prior to first dose of study drug.
Patients that have received systemic treatments within four weeks prior to the beginning of treatment
May have received one or more prior treatments with chemotherapy
No more than 3 previous treatments for cGVHD.
Ongoing toxic manifestations of previous treatments.
No more than 3 previous treatments for cGVHD, excluding topical agents.
For phase Ib, any line of prior treatments is permitted including prior neratinib and capecitabine
For phase II, up to 4 prior chemotherapy-based treatments are allowed; patients must have had prior trastuzumab-based therapy; prior neratinib treatment is not permitted; prior capecitabine is allowed, if not combined with neratinib
Prior therapy: there is no limit on the number of prior surgeries, radiation therapy treatments, radiosurgery treatments, or chemotherapy
Phase I patients: Histologic documentation of a solid malignancy and who have exhausted available standard medical treatments or for whom no standard treatments are currently available; this includes primary brain tumors
No prior treatment with bortezomib for cGVHD; participants may have received bortezomib for other reasons besides cGVHD (such as leukemia or solid tumor); any other previous treatments for cGVHD are allowed
Discontinued all prior cancer treatments for cancer & recovered from the acute effects of therapy
Phase Ib: Patients may have had any number of prior treatments, including 0, or prior pazopanib
Patients previously treated with herbal supplements, or other potential or experimental therapies for prostate cancer must have discontinued these treatments and completed at least a one-month washout prior to beginning treatment
Any of the following treatments, within the specified time frame, prior to the first dose of TAS4464:
Inadequate washout of prohibited hormonally active agents or other prior treatments for prostate cancer (PCa)
At least 3 weeks post any treatments/therapies at the time of first dose.
Direct bilirubin =< 1.5 mg/dl; Note: as many eligible patients will be pancytopenic secondary to their disease or prior treatments, hematologic abnormalities will not be used as a criteria for entry or exclusion
Patient has received any of the following treatments within the specified timeframe prior to dosing:
Patient has received any of the following treatments within the specified timeframe:
Prior Treatments:
Systemic treatments: Must have discontinued previous systemic treatments for cancer and recovered from the acute effects of therapy. Participants must have discontinued:
Treatments in this category include chemotherapy and targeted therapies not targeting VEGF; 14 days must have elapsed since discontinuation of prior chemotherapeutic treatments for glioma and study treatment
No prior use of EGFR tyrosine kinase inhibitors or monoclonal antibodies; all other prior treatments are allowed if >= 4 weeks since treatment completed, including chemotherapy (systemic or intraperitoneal), radiation therapy, and/or surgery; there is no limit on the number of previous treatments allowed
Recovered or stabilized from prior treatments.
Active severe personality disorders (defined according to DSM-IV). Note: for patients with psychotropic treatments ongoing at baseline, the dose and the schedule should not be modified within the previous 6 weeks prior to start of study drug.
Underwent resection, radiofrequency ablation, radiation or chemoembolization within 4 weeks before enrollment or not recovered from such treatments.
The participant has received 0 - 2 systemic anticancer regimens in addition to depot octreotide, which may have included chemotherapy, interferon, antiangiogenic therapy, other targeted treatments, or a combination of such treatments
Patients with lymphomas that are felt to be incurable with any therapy and for whom there are no standard treatments that would be anticipated to be necessary or beneficial within the next 5 months; these patients can have received any amount of prior chemotherapy to enter this trial
Subjects who have had treatments with GnRH agonists/antagonists and/or anti-androgens within 1 year of randomization
Prior chemotherapies are permitted, except with prior treatments with taxanes, vinca alcaloids, gemcitabine, eribulin, ixabepilone, platinum drugs
Previous or ongoing physical therapy treatments are acceptable
PATIENTS: Completed more than half of prescribed chemotherapy treatments
Be receiving hospital-based treatment so that acupressure treatments and parents can be trained and monitored
BCS will not be excluded based on cancer treatments received or a history of diagnosis of mild depression, anxiety, and hypertension and diabetes
colon cancer: 2-4 prior treatments
Individuals with previous radiation treatments to the breast or axilla areas
Are willing to refrain from using other treatments for oral mucositis until they consult with the study investigator(s).
Prohibited treatments and/or therapies:\r\n* Prior history of breast cancer surgery and/or radiotherapy
COHORT I: Initially treated with definitive local therapy (surgery and radiation therapy are the most common treatments, but other treatments are also eligible)
Prior use of radiosensitizers, Gliadel wafers, or other interstitial intracranial treatments
Has received treatment with any prescribed treatments within specified time frames prior to study drug administration
Advanced low or intermediate grade gastroenteropancreatic or lung or thymus neuroendocrine tumor (NET), or NET of unknown primary, progressed after at least 1 line of anticancer therapy (unless no standard treatments available or such treatments are deemed not appropriate)
Advanced paraganglioma, pheochromocytoma, medullary thyroid carcinoma, Merkel cell carcinoma, or high grade extrapulmonary neuroendocrine carcinoma having progressed after 1 or more lines of anticancer chemotherapy (unless no standard treatments available or such treatments are deemed not appropriate)
Be receiving any active pharmaceutical treatments for cancer
Patients may receive no other concurrent anticancer treatments such as chemotherapy, hormone therapy (except for prostate cancer patients on luteinizing hormone-releasing hormone ((LHRH)) agonists), immunotherapy, biological agents, investigational agents, or radiation therapy during this trial, and should be off these treatments for at least 2 weeks, or until they have completely recovered from the side effects of these treatments, whichever is longest, except for persistent grade 1 neuropathy in patients who received prior platinum or taxanes.
Patients must not be participating or plan to participate in other clinical trials that involve investigational systemic cancer treatments or investigational uses of CSF during their first 6 months after registration
Use of topical or systemic agents/treatments for OM within 2 weeks of treatment day 1.
Have discontinued all previous treatments for cancer and recovered from the acute effects of therapy.
